JAK2-IN-7
| Catalog Number | Pack Size | List Price* | Quantity | |
|---|---|---|---|---|
| HY-131906-5MG | 5 mg | 584,00 | Add | |
| HY-131906-10MMO | 10mM/1mL | 590,00 | Add | |
| HY-131906-10MG | 10 mg | 1'027,00 | Add | |
| HY-131906-25MG | 25 mg | 2'103,00 | Add | |
| HY-131906-50MG | 50 mg | 3'244,00 | Add | |
| HY-131906-100MG | 100 mg | 4'827,00 | Add |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Best price guarantee – we offer you the lowest price in Switzerland. Please contact us for a quote if needed.
JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities[1].
| Category | Inhibitor |
| Supplier | MedChem Express |
| Regulatory Status | RUO |
| Research Field | Cancer, Apoptosis,Epigenetics,JAK/STAT Signaling,Protein Tyrosine Kinase/RTK,Stem Cell/Wnt |
| Format | Solubility: DMSO : 250 mg/mL (ultrasonic) |
| Grade | Clinical information: No Development Reported |
| Purity | 99.15% |
| Molecular Formula | C26H33N7O |
| Molecular Weight | 459.59 |
| CAS-Number | 2593402-36-7 |
| Storage Conditions | -20°C, 3 years; 4°C, 2 years (Powder) |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.medchemexpress.com |
| Shipping Details | Room Temperature |
| Material Safety Data Sheet | Download PDF |
